These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 7905592)
21. Treatment of Truncal Incompetence and Varicose Veins with a Single Administration of a New Polidocanol Endovenous Microfoam Preparation Improves Symptoms and Appearance. King JT; O'Byrne M; Vasquez M; Wright D; Eur J Vasc Endovasc Surg; 2015 Dec; 50(6):784-93. PubMed ID: 26384639 [TBL] [Abstract][Full Text] [Related]
28. Late stroke after foam sclerotherapy. Hahn M; Schulz T; Jünger M Vasa; 2010 Feb; 39(1):108-10. PubMed ID: 20186684 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of Aethoxysklerol® (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Zhang J; Jing Z; Schliephake DE; Otto J; Malouf GM; Gu YQ Phlebology; 2012 Jun; 27(4):184-90. PubMed ID: 22045827 [TBL] [Abstract][Full Text] [Related]
31. Migraine ophthalmique with reversible scotomas after sclerotherapy with liquid 1% polidocanol. Künzlberger B; Pieck C; Altmeyer P; Stücker M Dermatol Surg; 2006 Nov; 32(11):1410-3. PubMed ID: 17083597 [No Abstract] [Full Text] [Related]
32. Sclerotherapy and foam sclerotherapy for varicose veins. Coleridge Smith P Phlebology; 2009 Dec; 24(6):260-9. PubMed ID: 19952382 [TBL] [Abstract][Full Text] [Related]
33. Foam sclerotherapy for spouting haemorrhage in patients with varicose veins. Hamahata A; Yamaki T; Osada A; Fujisawa D; Sakurai H Eur J Vasc Endovasc Surg; 2011 Jun; 41(6):856-8. PubMed ID: 21420881 [TBL] [Abstract][Full Text] [Related]
34. Transparietal diffusion of polidocanol: Potential complication of sclerotherapy? Ramelet AA; Bossart S Phlebology; 2023 Dec; 38(10):698-699. PubMed ID: 37644640 [No Abstract] [Full Text] [Related]
35. Re: Polidocanol concentration and time affect the properties of foam used for sclerotherapy. Cameron E Dermatol Surg; 2012 Feb; 38(2):290. PubMed ID: 22309639 [No Abstract] [Full Text] [Related]
37. Polidocanol versus hypertonic glucose for sclerotherapy treatment of reticular veins of the lower limbs: study protocol for a randomized controlled trial. Bertanha M; Sobreira ML; Pinheiro Lúcio Filho CE; de Oliveira Mariúba JV; Farres Pimenta RE; Jaldin RG; Moroz A; Moura R; Rollo HA; Yoshida WB Trials; 2014 Dec; 15():497. PubMed ID: 25527165 [TBL] [Abstract][Full Text] [Related]
38. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Todd KL; Wright DI; Phlebology; 2014 Oct; 29(9):608-18. PubMed ID: 23864535 [TBL] [Abstract][Full Text] [Related]
39. Sclerotherapy: review of results and complications in 200 patients. Puissegur Lupo ML J Dermatol Surg Oncol; 1989 Feb; 15(2):214-9. PubMed ID: 2915088 [TBL] [Abstract][Full Text] [Related]
40. 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Moreno-Moraga J; Smarandache A; Pascu ML; Royo J; Trelles MA Phlebology; 2014 Dec; 29(10):658-66. PubMed ID: 23989971 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]